The evolving understanding of risk with calcitonin gene‐related peptide monoclonal antibodies based on real‐world data: A focus on hypertension and Raynaud phenomenon

2021 ◽  
Author(s):  
Ilana D. Breen ◽  
Aaron R. Mangold ◽  
Juliana H. VanderPluym
Keyword(s):  
Monoclonal Antibodies ◽  
Real World ◽  
Calcitonin Gene Related Peptide ◽  
Real World Data ◽  
Raynaud Phenomenon ◽  
World Data ◽  
Related Peptide ◽  
Calcitonin Gene

scholarly journals PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

2021 ◽  
Author(s):  
Messoud Ashina ◽  
Faisal Mohammad Amin ◽  
Pinar Kokturk ◽  
Joshua M Cohen ◽  
Martijn Konings ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Real World ◽  
Real Life ◽  
Episodic Migraine ◽  
Calcitonin Gene Related Peptide ◽  
Real World Data ◽  
Related Peptide ◽  
Humanized Monoclonal Antibody ◽  
Calcitonin Gene ◽  
Acute Headache

Fremanezumab is a humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide and is approved in Europe for migraine prevention in adults with ≥4 migraine days/month. The Pan-European Real Life (PEARL) study is a 24-month, prospective, observational study of fremanezumab in chronic or episodic migraine. End points include proportion of patients with ≥50% reduction in monthly migraine days during 6 months of treatment (primary); changes in monthly migraine days, disability scores and acute headache medication use; adherence and persistence; and effectiveness in patients switching from another calcitonin gene-related peptide pathway-targeting monoclonal antibody. PEARL is being conducted in approximately 100 centers in 11 European countries (estimated n = 1100). PEARL will generate important real-world data on effectiveness of fremanezumab and treatment patterns in patients with chronic migraine or episodic migraine.

Calcitonin-Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention; Literature Review

2021 ◽  
Vol 10 (1) ◽  
pp. 48-51
Author(s):  
Haneen Ahmed Khouja ◽  
Rawan Awadh Alshehri ◽  
Hussain Mirza Alhalal ◽  
Hassan Dhafer Alabisi ◽  
Salhah Mohammad Alajmi ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Literature Review ◽  
Calcitonin Gene Related Peptide ◽  
Migraine Prevention ◽  
Related Peptide ◽  
Calcitonin Gene

Monoclonal antibodies distinguishing α and β forms of calcitonin gene-related peptide

1990 ◽  
Vol 134 (1) ◽  
pp. 87-94 ◽  
Author(s):  
D.P. Andrew ◽  
T.D. Bidgood ◽  
C. Bose ◽  
D. Brown ◽  
G. Galfre ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene

scholarly journals PRM11 Real-World Data to Calculate Cost-Effectiveness of Monoclonal Antibodies: Problems and Solutions

2012 ◽  
Vol 15 (7) ◽  
pp. A461-A462
Author(s):  
E.M. van Rooijen ◽  
N. van der Linden ◽  
C. van Gils ◽  
M. Oppe ◽  
C. Uyl-de Groot
Keyword(s):  
Monoclonal Antibodies ◽  
Cost Effectiveness ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
Problems And Solutions

Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials

Cephalalgia ◽  
2019 ◽  
Vol 39 (9) ◽  
pp. 1164-1179 ◽  
Author(s):  
Da Xu ◽  
Deng Chen ◽  
Li-na Zhu ◽  
Ge Tan ◽  
Hai-jiao Wang ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Adverse Events ◽  
Injection Site ◽  
Meta Analysis ◽  
Peptide Binding ◽  
Episodic Migraine ◽  
Calcitonin Gene Related Peptide ◽  
Serious Adverse Events ◽  
Related Peptide ◽  
Calcitonin Gene

Aim To systematically evaluate the safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies from the results of randomized controlled trials. Methods Online databases were searched on calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine. Overall withdrawal, withdrawal due to adverse events, adverse events, serious adverse events and specific adverse events were extracted from the included studies. A meta-analysis was performed with Revman 5.3.0 software. Results Ten studies that investigated four drugs (galcanezumab, erenumab, fremanezumab and eptinezumab) with 5817 participants were included in this study. Serious adverse events, overall withdrawals, withdrawal due to adverse events and any adverse events were not significantly associated with monoclonal antibody treatment. Injection site pain and erythema were significantly higher in the calcitonin-gene-related peptide binding monoclonal antibodies treatment group than in the placebo group. The rates of serious adverse events were significantly higher in the galcanezumab 120 mg group. Injection site erythema was associated with galcanezumab 120 mg and 240 mg. Injection site pain and nasopharyngitis were associated with galcanezumab 150 mg and 5 mg, respectively. Overall adverse events were significantly higher with erenumab 70 mg and 140 mg. Treatment-related adverse events were significantly higher with fremanezumab 225 mg/month and 675 mg/quarter. Conclusions This study provides data on the safety and tolerability profiles of calcitonin-gene-related peptide binding monoclonal antibodies and confirms their potential use as preventive treatments for episodic migraine. In addition to the acceptable withdrawal rates, serious adverse events were rare, and the severity of most adverse events was mild to moderate. Injection site reaction may be the major adverse event associated with galcanezumab.

Sign in / Sign up

Export Citation Format

Share Document